Coya Therapeutics, Inc.
COYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,554 | $6,002 | $0 | $0 |
| % Growth | -40.8% | – | – | – |
| Cost of Goods Sold | $11,866 | $5,502 | $4,412 | $0 |
| Gross Profit | -$8,312 | $501 | -$4,412 | $0 |
| % Margin | -233.9% | 8.3% | – | – |
| R&D Expenses | $11,891 | $6,045 | $4,937 | $2,542 |
| G&A Expenses | $8,886 | $7,833 | $4,847 | $2,312 |
| SG&A Expenses | $8,886 | $7,833 | $4,847 | $2,312 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$11,838 | -$5,474 | -$4,385 | $16 |
| Operating Expenses | $8,938 | $8,404 | $5,399 | $4,870 |
| Operating Income | -$17,250 | -$7,903 | -$9,812 | -$4,870 |
| % Margin | -485.4% | -131.7% | – | – |
| Other Income/Exp. Net | $1,649 | $639 | -$2,433 | -$21 |
| Pre-Tax Income | -$15,601 | -$7,264 | -$12,245 | -$4,892 |
| Tax Expense | -$720 | $724 | $0 | $0 |
| Net Income | -$14,881 | -$7,988 | -$12,245 | -$4,892 |
| % Margin | -418.7% | -133.1% | – | – |
| EPS | -0.98 | -0.79 | -1.231 | -0.74 |
| % Growth | -24.1% | 35.8% | -66.3% | – |
| EPS Diluted | -0.98 | -0.79 | -1.231 | -0.74 |
| Weighted Avg Shares Out | 15,239 | 10,164 | 9,948 | 6,603 |
| Weighted Avg Shares Out Dil | 15,239 | 10,164 | 9,948 | 6,603 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $27 | $27 | $27 | $16 |
| EBITDA | -$17,197 | -$7,333 | -$9,260 | -$4,854 |
| % Margin | -483.9% | -122.2% | – | – |